{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:51:46Z","timestamp":1790268706349,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.bioorg.2018.09.007","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T17:07:35Z","timestamp":1536340055000},"page":"425-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer"],"prefix":"10.1016","volume":"81","author":[{"given":"Wagdy M.","family":"Eldehna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4262-0323","authenticated-orcid":false,"given":"Alessio","family":"Nocentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Al-Rashood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada S.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamad M.","family":"Alkahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3342-702X","authenticated-orcid":false,"given":"Abdulrahman A.","family":"Almehizia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Reda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem A.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudiu T.","family":"Supuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2018.09.007_b0005","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nrd2467","article-title":"Carbonic anhydrases: novel therapeutic applications for inhibitors and activators","volume":"7","author":"Supuran","year":"2008","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.bioorg.2018.09.007_b0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/14756366.2015.1122001","article-title":"How many carbonic anhydrase inhibition mechanisms exist?","volume":"31","author":"Supuran","year":"2016","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0015","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1042\/BCJ20160115","article-title":"Structure and function of carbonic anhydrases","volume":"473","author":"Supuran","year":"2016","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2018.09.007_b0020","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1021\/cr200176r","article-title":"Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms?","volume":"112","author":"Alterio","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bioorg.2018.09.007_b0025","doi-asserted-by":"crossref","unstructured":"C.T. Supuran, V. Alterio, A. Di Fiore, K. D\u2019Ambrosio, F. Carta, S.M. Monti, G. De Simone, Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one, Med. Res. Rev. (2018) (in press) doi: 10.1002\/med.21497.","DOI":"10.1002\/med.21497"},{"key":"10.1016\/j.bioorg.2018.09.007_b0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/oncotarget.422","article-title":"Recent developments in targeting carbonic anhydrase IX for cancer therapeutics","volume":"3","author":"McDonald","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2018.09.007_b0035","first-page":"404","article-title":"Carbonic anhydrase IX: biochemical and crystallographic characterization of a novel antitumor target","volume":"2010","author":"De Simone","year":"1804","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2018.09.007_b0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/metabo7030048","article-title":"Carbonic anhydrase inhibition and the management of hypoxic tumors","volume":"7","author":"Supuran","year":"2017","journal-title":"Metabolites"},{"key":"10.1016\/j.bioorg.2018.09.007_b0045","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.bioorg.2018.01.021","article-title":"New anticancer drug candidates sulfonamides as selective hCA IX or hCA XII inhibitors","volume":"77","author":"Gul","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2018.04.016","article-title":"Dual-tail arylsulfone-based benzenesulfonamides differently match the hydrophobic and hydrophilic halves of human carbonic anhydrases active sites: Selective inhibitors for the tumor-associated hCA IX isoform","volume":"152","author":"Ibrahim","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0055","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejmech.2017.01.017","article-title":"Novel indolin-2-one-based sulfonamides as carbonic anhydrase inhibitors: synthesis, in vitro biological evaluation against carbonic anhydrases isoforms I, II, IV and VII and molecular docking studies","volume":"127","author":"Eldehna","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ejmech.2017.07.073","article-title":"Novel 4\/3-((4-oxo-5-(2-oxoindolin-3-ylidene) thiazolidin-2-ylidene) amino) benzenesulfonamides: synthesis, carbonic anhydrase inhibitory activity, anticancer activity and molecular modelling studies","volume":"139","author":"Eldehna","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ejmech.2016.01.030","article-title":"Amido\/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar\/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII","volume":"110","author":"Eldehna","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejmech.2015.09.021","article-title":"Isatin-pyrazole benzenesulfonamide hybrids potently inhibit tumor-associated carbonic anhydrase isoforms IX and XII","volume":"103","author":"Ibrahim","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0075","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.1039\/C5OB00688K","article-title":"Discovery of novel isatin-based sulfonamides with potent and selective inhibition of the tumor associated carbonic anhydrase isoforms IX and XII","volume":"13","author":"G\u00fczel-Akdemir","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0080","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1016\/j.bmc.2017.05.029","article-title":"Novel sulfonamide-containing 2-indolinones that selectively inhibit tumor-associated alpha carbonic anhydrases","volume":"25","author":"Karal\u0131","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/14756366.2016.1235042","article-title":"Isatin: a privileged scaffold for the design of carbonic anhydrase inhibitors","volume":"32","author":"Melis","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0090","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejmech.2018.07.054","article-title":"Novel hydrazido benzenesulfonamides-isatin conjugates: synthesis, carbonic anhydrase inhibitory activity and molecular modeling studies","volume":"157","author":"Abo-Ashour","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0095","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ejmech.2016.06.034","article-title":"3-Hydrazinoindolin-2-one derivatives: chemical classification and investigation of their targets as anticancer agents","volume":"122","author":"Ibrahim","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0100","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40265-014-0335-0","article-title":"Nintedanib: first global approval","volume":"75","author":"McCormack","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2018.09.007_b0105","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2018.09.007_b0110","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1080\/14756366.2017.1421181","article-title":"Novel [(3-indolylmethylene) hydrazono] indolin-2-ones as apoptotic anti-proliferative agents: design, synthesis and in vitro biological evaluation","volume":"33","author":"Eldehna","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181241","article-title":"New hydrazonoindolin-2-ones: synthesis, exploration of the possible anti-proliferative mechanism of action and encapsulation into PLGA microspheres","volume":"12","author":"Attia","year":"2017","journal-title":"PloS one"},{"key":"10.1016\/j.bioorg.2018.09.007_b0120","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.2147\/DDDT.S140164","article-title":"Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profiling","volume":"11","author":"Abdel-Aziz","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bioorg.2018.09.007_b0125","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1080\/14756366.2017.1279155","article-title":"Synthesis and in vitro anti-proliferative activity of some novel isatins conjugated with quinazoline\/phthalazine hydrazines against triple-negative breast cancer MDA-MB-231 cells as apoptosis-inducing agents","volume":"32","author":"Eldehna","year":"2017","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0130","doi-asserted-by":"crossref","unstructured":"H.A. Abdel-Aziz, H.A. Ghabbour, W.M. Eldehna, M.M. Qabeel, H.-K. Fun, synthesis, crystal structure, and biological activity of cis\/trans amide rotomers of (Z)-N'-(2-oxoindolin-3-ylidene)formohydrazide, J. Chem. (2014) Article ID 760434, 7 pages.","DOI":"10.1155\/2014\/760434"},{"key":"10.1016\/j.bioorg.2018.09.007_b0135","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3390\/molecules21060762","article-title":"Synthesis and cytotoxic activity of biphenylurea derivatives containing indolin-2-one moieties","volume":"21","author":"Eldehna","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2018.09.007_b0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejmech.2015.05.040","article-title":"Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: synthesis, in vitro biological evaluation and molecular docking","volume":"100","author":"Eldehna","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0145","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1016\/S0021-9258(18)62326-9","article-title":"The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes B and C","volume":"246","author":"Khalifah","year":"1971","journal-title":"J. Biol. Chem."},{"key":"#cr-split#-10.1016\/j.bioorg.2018.09.007_b0150.1","unstructured":"(a) E. Korkeila, K. Talvinen, P.M. Jaakkola, H. Minn, K. Syrj??nen, J. Sundstr??m, S. Pyrh??nen, Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer, Br. J. Cancer. 100 (2009) 874???880."},{"key":"#cr-split#-10.1016\/j.bioorg.2018.09.007_b0150.2","unstructured":"(b) A.M. Alafeefy, R. Ahmad, M. Abdulla, W.M. Eldehna, A.M.S. Al-Tamimi, H.A. Abdel-Aziz, O. Al-Obaid, F. Carta, A.A. Al-Kahtani, C.T. Supuran, Development of certain new 2-substituted-quinazolin-4-yl-aminobenzenesulfonamide as potential antitumor agents, Eur. J. Med. Chem. 109 (2016) 247???253."},{"key":"10.1016\/j.bioorg.2018.09.007_b0155","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/ijc.22436","article-title":"HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome","volume":"120","author":"Trastour","year":"2007","journal-title":"Int. J. Cancer."},{"key":"10.1016\/j.bioorg.2018.09.007_b0160","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bjc.2015.85","article-title":"Mitochondrial apoptosis: killing cancer using the enemy within","volume":"112","author":"Lopez","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2018.09.007_b0165","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S1470-2045(03)01277-4","article-title":"Anticancer therapy targeting the apoptotic pathway","volume":"4","author":"Hu","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bioorg.2018.09.007_b0170","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.2147\/OTT.S148108","article-title":"novel quinazoline-based sulfonamide derivative (3D) induces apoptosis in colorectal cancer by inhibiting JaK2\u2013sTaT3 pathway","volume":"11","author":"Al-Obeed","year":"2018","journal-title":"Onco Targets Ther."},{"key":"10.1016\/j.bioorg.2018.09.007_b0175","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.bioorg.2018.01.034","article-title":"Development of novel synthesized phthalazinone-based PARP-1 inhibitors with apoptosis inducing mechanism in lung cancer","volume":"77","author":"Almahli","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0180","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/14756366.2017.1417276","article-title":"One-pot three-component synthesis of novel spirooxindoles with potential cytotoxic activity against triple-negative breast cancer MDAMB-231 cells","volume":"33","author":"Eldehna","year":"2018","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0185","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.3390\/molecules23061420","article-title":"Novel thiazolidinone\/thiazolo [3, 2-a] benzimidazolone-isatin conjugates as apoptotic anti-proliferative agents towards breast cancer: one-pot synthesis and in vitro biological evaluation","volume":"23","author":"El-Naggar","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2018.09.007_b0190","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrm2308","article-title":"The BCL-2 protein family: opposing activities that mediate cell death","volume":"9","author":"Youle","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2018.09.007_b0195","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/sj.cdd.4400453","article-title":"An elevated bax\/bcl-2 ratio corresponds with the onset of prostate epithelial cell apoptosis","volume":"6","author":"Perlman","year":"1999","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.bioorg.2018.09.007_b0200","doi-asserted-by":"crossref","first-page":"6194","DOI":"10.1038\/onc.2008.297","article-title":"Caspases in apoptosis and beyond","volume":"27","author":"Li","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2018.09.007_b0205","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1038\/sj.onc.1207116","article-title":"Control of apoptosis by p53","volume":"22","author":"Fridman","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.bioorg.2018.09.007_b0210","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/20959","article-title":"Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC","volume":"399","author":"Shimizu","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2018.09.007_b0215","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1016\/j.bmc.2017.02.037","article-title":"Synthesis of bulky-tailed sulfonamides incorporating pyrido [2, 3-d][1, 2, 4] triazolo [4, 3-a] pyrimidin-1 (5H)-yl) moieties and evaluation of their carbonic anhydrases I, II, IV and IX inhibitory effects","volume":"25","author":"Fares","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_h0220","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bioorg.2018.02.021","article-title":"Supuran Synthesis and biological evaluation of novel pyrazoline-based aromatic sulfamates with potent carbonic anhydrase isoforms II, IV and IX inhibitory efficacy","volume":"77","author":"A. Nocentini, D. Moi, G. Balboni, S. Salvadori, V. Onnis, C.T.","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_h0225","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ejmech.2018.04.002","article-title":"2-Benzylpiperazine: a new scaffold for potent human carbonic anhydrase inhibitors. Synthesis, enzyme inhibition, enantioselectivity, computational and crystallographic studies and in vivo activity for a new class of intraocular pressure lowering agents","volume":"151","author":"Chiaramonte","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"#cr-split#-10.1016\/j.bioorg.2018.09.007_b0225.1","doi-asserted-by":"crossref","unstructured":"(a) H.A. Abdel-Aziz, H.A. Ghabbour, W.M. Eldehna, S.T.A. Al-Rashood, K.A. Al-Rashood, H.-K. Fun, M. Al-Tahhan, A. Al-Dhfyan, 2-((Benzimidazol-2-yl)thio)-1-arylethan-1-ones: synthesis, crystal study and cancer stem cells CD133 targeting potential, Eur. J. Med. Chem. 104 (2015) 1-10.","DOI":"10.1016\/j.ejmech.2015.09.023"},{"key":"#cr-split#-10.1016\/j.bioorg.2018.09.007_b0225.2","doi-asserted-by":"crossref","unstructured":"(b) H.A. Abdel-Aziz, W.M. Eldehna, H. Ghabbour, G.H. Al-Ansary, A.M. Assaf, A. Al-Dhfyan, Synthesis, crystal study, and anti-proliferative activity of some 2-benzimidazolylthioacetophenones towards triple-negative breast cancer MDA-MB-468 cells as apoptosis-inducing agents, Int. J. Mol. Sci. 17 (2016) 1221.","DOI":"10.3390\/ijms17081221"},{"key":"#cr-split#-10.1016\/j.bioorg.2018.09.007_b0225.3","unstructured":"(c) G.H. Al-Ansary, W.M. Eldehna, H. Ghabbour, S.T. Al-Rashood, K.A. Al-Rashood, R.A. Eladwy, A. Al-Dhfyan, M.M. Kabil, H.A. Abdel-Aziz, Cancer stem cells CD133 inhibition and cytotoxicity of certain 3-phenylthiazolo [3, 2-a] benzimidazoles: Design, direct synthesis, crystal study and In Vitro biological evaluation. J. Enzym. Inhib. Med. Chem. 32 (2017) 986???991."},{"key":"10.1016\/j.bioorg.2018.09.007_b0230","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14756366.2018.1477137","article-title":"Novel coumarin-6-sulfonamides as apoptotic anti-proliferative agents: synthesis, in vitro biological evaluation, and QSAR studies","volume":"33","author":"Sabt","year":"2018","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2018.09.007_b0235","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ejmech.2014.10.064","article-title":"Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl\/benzylphthalazin-1-ones","volume":"89","author":"Eldehna","year":"2015","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818307855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206818307855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T23:18:55Z","timestamp":1693869535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206818307855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":51,"alternative-id":["S0045206818307855"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2018.09.007","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumor-associated carbonic anhydrase isoform IX and XII inhibitory properties of certain isatin-bearing sulfonamides endowed with in vitro antitumor activity towards colon cancer","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2018.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}